Posted by Jakeman on June 15, 2006, at 1:22:28
In reply to Re: EMSAM stronger than oral selegline, posted by notfred on June 14, 2006, at 17:50:40
>
> >
> > b. MAO-A inhibition is what produces antidepressant efficacy
>Other studies have shown that antidepressant efficacy for transdermal selelinge is provided at lower doses(6 mg) See below. Which may indicate that transdermal delivery has a stronger effect. Maybe its hitting both A and B. I don't know.
http://www.rxlist.com/cgi/generic4/emsam_cp.htm
Clinical Efficacy TrialsThe efficacy of EMSAM as a treatment for major depressive disorder was established in two placebo-controlled studies of six and eight weeks duration in adult outpatients (ages 18 to 70 years) meeting DSM-IV criteria for major depressive disorder. In both studies, patients were randomized to double-blind treatment with EMSAM or placebo. The 6-week trial (N=176) showed that EMSAM 6mg/24hours was significantly more effective than placebo on the 17-item Hamilton Depression Rating Scale (HAM-D). In an 8-week dose titration trial, depressed patients (N=265), who received EMSAM or placebo at a starting dose of 6mg/24hours, with possible increases to 9mg/24hours or 12mg/24hours based on clinical response, showed significant improvement compared with placebo on the primary outcome measure, the 28-item HAM-D total score.
In another trial, 322 patients meeting DSM-IV criteria for major depressive disorder who had responded during an initial 10-week open-label treatment phase for about 25 days, on average, to EMSAM 6mg/24hours, were randomized either to continuation of EMSAM at the same dose (N=159) or to placebo (N=163) under double-blind conditions for observation of relapse. About 52% of the EMSAM-treated patients, as well as about 52% of the placebo-treated patients, had discontinued treatment by week 12 of the double-blind phase. Response during the open-label phase was defined as 17-item HAM-D score <10 at either week 8 or 9 and at week 10 of the open-label phase. Relapse during the double-blind phase was defined as follows : (1) a 17-item HAM-D score ³ 14, (2) a CGI-S score of ³ 3 (with at least a 2-point increase from double-blind baseline), and (3) meeting DSM-IV criteria for major depressive disorder on two consecutive visits ³ 11 days apart. In the double-blind phase, patients receiving continued EMSAM experienced a significantly longer time to relapse
poster:Jakeman
thread:655515
URL: http://www.dr-bob.org/babble/20060610/msgs/657149.html